As of the 25th April 2022, Deepbridge Capital is proud to announce that it has deployed a record £31.5 million into early-stage technology and life sciences companies during the 2021/22 tax year, up from £29.4 million in 2020/21.
Summary of the Deepbridge Explore Webinar
Simon Tutton, Regional Director (South West England and South Wales), Deepbridge Capital
Andrew Aldridge, Partner and Head of Marketing at Deepbridge, recently spoke with Professional Adviser to share his thoughts regarding the world of tax-efficient investments and assesses which relief is the trump card for advisers and clients.
Deepbridge Capital has been shortlisted for the Deal of the Year (Transaction size below £2.5 million) Award at the upcoming 2022 Insider Media, Northern Ireland Dealmakers Awards.
Deepbridge Capital has deployed over £50 million of capital into UK life sciences companies.
The Deepbridge Life Sciences EIS was launched in 2017 as our first life sciences focused EIS fund, providing private investors with access to a portfolio of early-stage investee companies across the biopharmaceutical, biotechnology, medical technology and digital healthcare sectors.
